Blake Martell

Cooley advised Founders Fund, a venture capital firm investing in smart people solving difficult problems, as a co-lead investor in Anduril Industries’ $1.5 billion Series F funding round, which increased Anduril’s valuation to $14 billion.

Cooley advised Lacework, a data-driven cloud security company, on its definitive agreement to be acquired by Fortinet (Nasdaq: FTNT), the global cybersecurity leader driving the convergence of networking and security.

Cooley advised Delphix, a vendor of test data management software, on its acquisition by Perforce, a provider of solutions to enterprise teams requiring productivity, visibility and scale along the development life cycle.

Cooley advised COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, on the close of its $105 million Series A financing.

Cooley advised Inscripta, a global leader in genome engineering technology, on its acquisition of Infinome Biosciences and Sestina Bio. These acquisitions advance Inscripta’s strategy to develop and commercialize biomanufactured products for a broad spectrum of industrial and consumer markets. They also demonstrate Inscripta’s confidence in the commercial potential of the bioeconomy and the power of genome engineering to accelerate biomanufacturing innovation. Partner Mike Nelson led the Cooley team.